MX350964B - Formulaciones de agonistas del receptor de somatostatina. - Google Patents

Formulaciones de agonistas del receptor de somatostatina.

Info

Publication number
MX350964B
MX350964B MX2014014379A MX2014014379A MX350964B MX 350964 B MX350964 B MX 350964B MX 2014014379 A MX2014014379 A MX 2014014379A MX 2014014379 A MX2014014379 A MX 2014014379A MX 350964 B MX350964 B MX 350964B
Authority
MX
Mexico
Prior art keywords
receptor agonist
somatostatin receptor
compositions
forming
formulations
Prior art date
Application number
MX2014014379A
Other languages
English (en)
Other versions
MX2014014379A (es
Inventor
Tiberg Fredrik
Nistor Catalin
Johnsson Markus
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49623188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX350964(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2012/059917 external-priority patent/WO2012160213A1/en
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of MX2014014379A publication Critical patent/MX2014014379A/es
Publication of MX350964B publication Critical patent/MX350964B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Abstract

La presente invención se refiere a composiciones que forman una mezcla de baja viscosidad de: a) 20-50 % en peso de al menos un diacilglicerol; b) 20-54 %en peso de al menos una fosfatidil colina (PC); c) 5-15 % en peso de al menos un solvente mono-alcohólico orgánico y biocompatible; d) 1 a 20 % en peso de solvente polar e) 5 a 150 mg/ml de al menos un agonista del receptor de somatostatina de péptido que comprende pasireotida; f) opcionalmente al menos un antioxidante; en donde la relación de componentes a:b se encuentra en el intervalo de 40:60 a 54:46; en donde la preformulación forma, o tiene la capacidad de formar, al menos una estructura de fase cristalina líquida tras el contacto con fluido acuoso en exceso. La invención se refiere adicionalmente a métodos de tratamiento que comprenden la administración de tales composiciones y a dispositivos de administración precargados y kits que contienen las formulaciones.
MX2014014379A 2012-05-25 2013-05-24 Formulaciones de agonistas del receptor de somatostatina. MX350964B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2012/059917 WO2012160213A1 (en) 2011-05-25 2012-05-25 Controlled release peptide formulations
US201261730613P 2012-11-28 2012-11-28
PCT/EP2013/060739 WO2013174978A1 (en) 2012-05-25 2013-05-24 Somatostatin receptor agonist formulations

Publications (2)

Publication Number Publication Date
MX2014014379A MX2014014379A (es) 2015-02-05
MX350964B true MX350964B (es) 2017-09-27

Family

ID=49623188

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014379A MX350964B (es) 2012-05-25 2013-05-24 Formulaciones de agonistas del receptor de somatostatina.

Country Status (23)

Country Link
US (2) US11672843B2 (es)
JP (1) JP6374380B2 (es)
KR (1) KR102139080B1 (es)
CN (1) CN104487050B (es)
AU (1) AU2013265210B2 (es)
BR (1) BR112014029425A2 (es)
CA (1) CA2874367C (es)
CL (1) CL2014003185A1 (es)
CO (1) CO7160067A2 (es)
DK (1) DK2861209T3 (es)
EA (1) EA035495B1 (es)
ES (1) ES2834318T3 (es)
HK (1) HK1207985A1 (es)
IL (1) IL235740A0 (es)
IN (1) IN2014DN09831A (es)
MA (1) MA37672A1 (es)
MX (1) MX350964B (es)
NZ (1) NZ702028A (es)
PE (1) PE20150195A1 (es)
PH (1) PH12014502614A1 (es)
SG (1) SG11201407678YA (es)
TN (1) TN2014000483A1 (es)
WO (1) WO2013174978A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2390331C2 (ru) * 2004-06-04 2010-05-27 Камурус Аб Жидкие депо-препараты
US11433120B2 (en) * 2011-05-25 2022-09-06 Camurus Ab Controlled release peptide formulations
WO2018060213A1 (en) * 2016-09-27 2018-04-05 Camurus Ab Formulations containing a somatostatin receptor agonist
CN113018248B (zh) * 2019-12-23 2022-07-22 南京清普生物科技有限公司 一种缓释递药系统
CN114240934B (zh) * 2022-02-21 2022-05-10 深圳大学 一种基于肢端肥大症的图像数据分析方法及系统

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5340802A (en) 1989-06-30 1994-08-23 Abbott Laboratories Peptide analog type-B CCK receptor ligands
CA2535463A1 (en) 1989-07-07 1991-01-08 Novartis Ag Octreotide-pamoate and its use in sustained release formulations of water soluble peptides
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
WO1993006921A1 (en) 1991-10-04 1993-04-15 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
ATE182278T1 (de) 1991-10-04 1999-08-15 Gs Dev Ab Teilchen, methode zur herstellung der teilchen und deren verwendung
US6228383B1 (en) 1994-03-03 2001-05-08 Gs Development Ab Use of fatty acid esters as bioadhesive substances
CA2186750C (en) 1994-03-30 2008-08-05 Jens Hansen Use of fatty acid esters as bioadhesive substances
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
FR2725369B1 (fr) 1994-10-07 1997-01-03 Oreal Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire
AU702030B2 (en) 1995-10-12 1999-02-11 Gs Development Ab A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
JP2001524958A (ja) 1997-04-17 2001-12-04 ジーエス ディベロップメント アクティエボラーグ 新規な液晶をベースとする生物接着性薬剤送出系
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US20040018241A1 (en) 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
SI1140148T1 (sl) 1998-12-22 2006-04-30 Lilly Co Eli Stabilna formulacija raztopine glukagonu podobnega peptida-1
US6011067A (en) 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US20020153508A1 (en) 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
US7008646B2 (en) 2001-02-20 2006-03-07 Patrick Thomas Spicer Cubic liquid crystalline compositions and methods for their preparation
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6656385B2 (en) 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
CA2451432A1 (en) 2001-06-23 2003-01-03 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
DK1412384T3 (da) 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
US7622118B2 (en) 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0305941D0 (en) 2003-03-14 2003-04-23 Camurus Ab Composition
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds
ATE411101T1 (de) 2003-08-04 2008-10-15 Camurus Ab Verfahren zum beladen von amphiphilen teilchen mit wirkstoffen
EP1663295A2 (en) 2003-09-01 2006-06-07 Novo Nordisk A/S Stable formulations of peptides
GB0322033D0 (en) 2003-09-19 2003-10-22 Camurus Ab Composition
DK1682091T3 (en) 2003-11-07 2017-05-15 Camurus Ab COMPOSITIONS OF LIPIDS AND CATIONIC PEPTIDES
WO2005063213A1 (en) 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
GB0401513D0 (en) 2004-01-23 2004-02-25 Camurus Ab Compositions
DE602005025083D1 (es) 2004-01-23 2011-01-13 Camurus Ab
RU2390331C2 (ru) 2004-06-04 2010-05-27 Камурус Аб Жидкие депо-препараты
CA2575906C (en) 2004-08-04 2014-04-15 Camurus Ab Compositions forming non-lamellar dispersions
ES2400034T3 (es) 2005-01-14 2013-04-05 Camurus Ab Formulaciones bioadhesivas tópicas
CA2594710C (en) 2005-01-14 2011-01-25 Camurus Ab Topical bioadhesive formulations
DE602005026998D1 (de) 2005-01-14 2011-04-28 Camurus Ab Somatostatin-analog-formulierungen
PL1843746T3 (pl) * 2005-01-14 2011-09-30 Camurus Ab Formulacje analogów somatostatyny
KR101245022B1 (ko) 2005-01-21 2013-03-19 카무러스 에이비 약제학적 지질 조성물
DK1888031T3 (da) 2005-06-06 2013-02-18 Camurus Ab GLP-1-analogformuleringer
CA2629300C (en) 2005-11-17 2014-07-08 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
AR066677A1 (es) * 2007-05-24 2009-09-02 Novartis Ag Formulacion de pasireotida. composicion farmaceutica para liberacion prolongada. microparticulas.
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
PT2310042E (pt) * 2008-07-08 2013-03-11 Novartis Ag Uso de pasireotido para o tratamento de hipoglicemia hiperinsulinémica endógena
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
US11433120B2 (en) * 2011-05-25 2022-09-06 Camurus Ab Controlled release peptide formulations
CN104093399B (zh) * 2011-12-05 2018-03-13 卡穆鲁斯公司 鲁棒性控释肽制剂

Also Published As

Publication number Publication date
AU2013265210A1 (en) 2014-12-04
NZ702028A (en) 2016-07-29
TN2014000483A1 (en) 2016-03-30
CA2874367C (en) 2020-08-18
MX2014014379A (es) 2015-02-05
SG11201407678YA (en) 2014-12-30
CL2014003185A1 (es) 2015-04-24
PE20150195A1 (es) 2015-02-27
US11672843B2 (en) 2023-06-13
EA035495B1 (ru) 2020-06-25
ES2834318T3 (es) 2021-06-17
CN104487050B (zh) 2019-08-20
HK1207985A1 (en) 2016-02-19
IN2014DN09831A (es) 2015-08-07
AU2013265210B2 (en) 2016-09-15
EA201491928A1 (ru) 2015-09-30
WO2013174978A1 (en) 2013-11-28
KR20150016977A (ko) 2015-02-13
CA2874367A1 (en) 2013-11-28
BR112014029425A2 (pt) 2017-06-27
JP2015520762A (ja) 2015-07-23
KR102139080B1 (ko) 2020-07-29
US20150105332A1 (en) 2015-04-16
CN104487050A (zh) 2015-04-01
DK2861209T3 (da) 2020-12-21
MA37672A1 (fr) 2016-07-29
PH12014502614A1 (en) 2015-01-21
JP6374380B2 (ja) 2018-08-15
CO7160067A2 (es) 2015-01-15
US20230372436A1 (en) 2023-11-23
IL235740A0 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
MX361716B (es) Formulaciones peptidicas de liberacion controlada.
MX350929B (es) Formulaciones peptidicas robustas de liberación controlada.
TN2014000483A1 (en) Somatostatin receptor agonist formulations
MX2018003333A (es) Formulaciones de liberacion controlada.
MX2013002932A (es) Formulaciones agricolas liquidas de estabilidad mejorada.
CL2015003290A1 (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4).
ATE501710T1 (de) Somatostatin-analog-formulierungen
PE20130402A1 (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
EA201791166A1 (ru) Препараты с контролируемым высвобождением
IL251413B2 (en) Composition of injectable buprenorphine
MX363963B (es) Composiciones de mentol liquidas.
MX2019002999A (es) Formulaciones de analogo de prostaciclina.
GEP20156218B (en) Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di-hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
EA201201480A1 (ru) Адгезионные ретардированные составы для местного применения куркумина
BR112015023750A2 (pt) composição agricolamente ativa concentrada; método de preparação da composição pronta para uso; composição pronta para uso; e método para o tratamento de uma planta
IN2013MU03800A (es)
TH1301006692A (th) สูตรผสมเปปไทด์ที่ปลดปล่อยยาในอัตราคงที่
PL412101A1 (pl) Mieszanina lotnych związków organicznych przeznaczonych do odstraszania owadów
BR112018001637A2 (pt) concentrado contendo alprostadil
IN2013DE00762A (es)
TH161414B (th) สูตรผสมโอปิออยด์
TH162713A (th) ยาชนิดรวมที่ประกอบรวมด้วยเจมิกลิปทินและเมตฟอร์มินและวิธีการสำหรับ การเตรียมยาชนิดรวมดังกล่าว

Legal Events

Date Code Title Description
FG Grant or registration